Myriad advances FDA application for cancer drug companion Dx test

04/8/2014 | GenomeWeb Daily News (free registration)

The first module of Myriad Genetics' premarket approval application for its BRACAnalysis test has been forwarded to the FDA. The company is seeking to have the assay approved for use as a companion diagnostic to identify ovarian cancer patients who would most likely benefit from AstraZeneca's experimental drug olaparib by identifying those with BRCA mutations.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN